Latest news with #REVB
Yahoo
30-05-2025
- Business
- Yahoo
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering
Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company dedicated to rebalancing inflammation for improved health outcomes, has successfully closed a public offering, raising approximately $4 million in gross proceeds. The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares, all priced at $1.10 per share and warrant. The warrants, exercisable upon shareholder approval, will remain valid for five years from their initial exercise date. Roth Capital Partners served as the sole placement agent for the transaction. A female doctor using the latest healthcare IT technology in her medical practice. Revelation Biosciences, Inc. (NASDAQ:REVB) plans to use the net proceeds to advance its clinical and preclinical programs. Key initiatives include completing its ongoing Phase 1b clinical trial, manufacturing clinical drug supplies, conducting additional preclinical studies for multiple indications, developing new products and therapies, and supporting general corporate operations. While we acknowledge the potential of REVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
21-05-2025
- Business
- Reuters
UK's Revolution Beauty explores sale after takeover approach
May 21 (Reuters) - British makeup and skin care retailer Revolution Beauty (REVB.L), opens new tab said on Wednesday it was exploring a sale after it received a preliminary takeover approach. The move comes days after the company said it was reviewing its funding structure and mulling a fundraise from key shareholders after its annual sales slumped by more than a quarter. The company did not disclose the identity of the potential bidder. Revolution Beauty had a market capitalization of 16.6 million pounds ($22.3 million) as of Tuesday's close. ($1 = 0.7435 pounds)
Yahoo
10-04-2025
- Business
- Yahoo
Why Revelation Biosciences Inc. (REVB) Went Down On Thursday?
We recently published a list of . In this article, we are going to take a look at where Revelation Biosciences Inc. (NASDAQ:REVB) stands against other stocks that fall behind amid market optimism. Wall Street's main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that the US will pause the imposition of higher tariffs on 75 countries for 90 days. In a post on Truth Social, Trump said that more than 75 countries have called to negotiate and have not retaliated in any way. 'I have authorized a 90-day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effective immediately,' he noted. Following the announcement, the Dow Jones jumped by 7.87 percent, the S&P 500 surged by 9.52 percent, and the tech-heavy Nasdaq soared by 12.16 percent. Despite the overall market optimism, 10 companies, predominantly in the biopharmaceutical sector, registered losses amid the lack of fresh developments to spark buying appetite. In this article, we listed Wednesday's 10 worst performers and detailed the reasons behind their drop. To come up with the list, we considered only the stocks with over $1 million in trading volume. A scientist in a lab coat examining a sample of cells through a microscope, illuminated by the bright laboratory lights. Revelation Biosciences dropped by 13.28 percent on Wednesday to close at $3.2 apiece as investors sold off positions for higher-yielding assets amid the lack of fresh developments. In recent news, REVB announced positive results in the clinical trials for REVTx-300 and REVTx-100 for the potential treatment of acute and chronic organ disease and the prevention and treatment of infection. According to the company, the studies, under what it named the Gemini project, showed a reduction in the inflammatory response in human peripheral blood mononuclear cells (PBMCs) that were exposed to clinically relevant molecules on inflammation. Human PBMCs were primed with either Gemini or placebo followed by a challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1 (HMGB-1) and lipopolysaccharide (LPS) in vitro. Overall, REVB ranks 4th on our list of stocks that fall behind amid market optimism. While we acknowledge the potential of REVB as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than REVB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
28-03-2025
- Business
- Yahoo
Should You Investigate Revolution Beauty Group plc (LON:REVB) At UK£0.13?
Revolution Beauty Group plc (LON:REVB), is not the largest company out there, but it saw a significant share price rise of 25% in the past couple of months on the AIM. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, what if the stock is still a bargain? Let's examine Revolution Beauty Group's valuation and outlook in more detail to determine if there's still a bargain opportunity. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The stock seems fairly valued at the moment according to our valuation model. It's trading around 8.6% below our intrinsic value, which means if you buy Revolution Beauty Group today, you'd be paying a reasonable price for it. And if you believe that the stock is really worth £0.14, then there isn't much room for the share price grow beyond what it's currently trading. Although, there may be an opportunity to buy in the future. This is because Revolution Beauty Group's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. See our latest analysis for Revolution Beauty Group Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. However, with an extremely negative double-digit change in profit expected next year, near-term growth is certainly not a driver of a buy decision. It seems like high uncertainty is on the cards for Revolution Beauty Group, at least in the near future. Are you a shareholder? REVB seems fairly priced right now, but given the uncertainty from negative returns in the future, this could be the right time to reduce the risk in your portfolio. Is your current exposure to the stock optimal for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on the stock, take a look at whether its fundamentals have changed. Are you a potential investor? If you've been keeping an eye on REVB for a while, now may not be the most advantageous time to buy, given it is trading around its fair value. The price seems to be trading at fair value, which means there's less benefit from mispricing. In addition to this, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven't considered today, which can help gel your views on REVB should the price fluctuate below its true value. If you'd like to know more about Revolution Beauty Group as a business, it's important to be aware of any risks it's facing. Our analysis shows 3 warning signs for Revolution Beauty Group (2 are concerning!) and we strongly recommend you look at these before investing. If you are no longer interested in Revolution Beauty Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
15-02-2025
- Business
- Yahoo
An Intrinsic Calculation For Revolution Beauty Group plc (LON:REVB) Suggests It's 46% Undervalued
Using the 2 Stage Free Cash Flow to Equity, Revolution Beauty Group fair value estimate is UK£0.21 Revolution Beauty Group is estimated to be 46% undervalued based on current share price of UK£0.11 Analyst price target for REVB is UK£0.50, which is 139% above our fair value estimate Today we will run through one way of estimating the intrinsic value of Revolution Beauty Group plc (LON:REVB) by taking the expected future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. Believe it or not, it's not too difficult to follow, as you'll see from our example! Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. See our latest analysis for Revolution Beauty Group We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (£, Millions) -UK£3.01m UK£280.2k UK£3.70m UK£4.61m UK£5.45m UK£6.17m UK£6.79m UK£7.31m UK£7.76m UK£8.14m Growth Rate Estimate Source Analyst x2 Analyst x2 Analyst x2 Est @ 24.82% Est @ 18.07% Est @ 13.34% Est @ 10.02% Est @ 7.71% Est @ 6.09% Est @ 4.95% Present Value (£, Millions) Discounted @ 9.9% -UK£2.7 UK£0.2 UK£2.8 UK£3.2 UK£3.4 UK£3.5 UK£3.5 UK£3.4 UK£3.3 UK£3.2 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = UK£24m The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.3%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 9.9%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = UK£8.1m× (1 + 2.3%) ÷ (9.9%– 2.3%) = UK£110m Present Value of Terminal Value (PVTV)= TV / (1 + r)10= UK£110m÷ ( 1 + 9.9%)10= UK£43m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is UK£67m. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of UK£0.1, the company appears quite undervalued at a 46% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Revolution Beauty Group as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 9.9%, which is based on a levered beta of 1.474. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Strength Debt is well covered by earnings and cashflows. Weakness No major weaknesses identified for REVB. Opportunity Has sufficient cash runway for more than 3 years based on current free cash flows. Good value based on P/S ratio and estimated fair value. Threat Total liabilities exceed total assets, which raises the risk of financial distress. Revenue is forecast to decrease over the next 2 years. Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Can we work out why the company is trading at a discount to intrinsic value? For Revolution Beauty Group, there are three relevant elements you should look at: Risks: As an example, we've found 3 warning signs for Revolution Beauty Group (2 can't be ignored!) that you need to consider before investing here. Future Earnings: How does REVB's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the AIM every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
